Comparative Pharmacology
Head-to-head clinical analysis: AMRIX versus NORFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMRIX versus NORFLEX.
AMRIX vs NORFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant